Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Long-term L-Triiodothyronine (T3) treatment in stable systolic heart failure patients: A randomised, double-blind, cross-over, placebo-controlled intervention study

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Sex differences in acromegaly at diagnosis: A nationwide cohort study and meta-analysis of the literature

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Increased levels of inflammatory factors are associated with severity of polyneuropathy in type 1 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Reproductive Hormones During Pubertal Transition in Girls with Transient Thelarche

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Phenotypic and genotypic features of a large kindred with a germline AIP variant

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Changes in subtypes of overt thyrotoxicosis and hypothyroidism following iodine fortification

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Chronic heart failure (HF) is characterized by reduced serum T3 levels and increased activity of the T3 degrading enzyme deiodinase D3. This may result in an intracellular composition of the cardiomyocyte mimicking that of hypothyroidism. Short-term T3-administration to systolic HF patients might be beneficial.

QUESTION: Does long-term treatment with T3 have a beneficial effect on cardiac function and neurohormonal activation in chronic systolic HF patients with serum T3 levels below 1.6 nmol/L? Design: A randomised, double-blind, cross-over, placebo-controlled intervention study with oral T3 treatment twice daily for 3 months. The T3 dose was up-titrated to a final dose avoiding reduced TSH levels.

PRIMARY END POINT: Left ventricular ejection fraction (LVEF).

METHODS: Cardiac imaging was performed using multiple gated tomographic radionuclide ventriculography (MUGA-SPECT). Neurohormonal stimulation was evaluated by plasma measurements of natriuretic peptides, aldosterone, renin, norepinephrine, and copeptin levels. The patients were monitored for potential cardiac arrhythmias at the start of each treatment period.

RESULTS: Thirteen patients completed the protocol. Mean LVEF was 43%, range: 37-52, and serum T3 levels 1.4 nmol/L (0.9-1.6). The T3 dose was 20 μg per day (10-40). TSH levels did not change between groups, whereas serum T3 levels increased in the active arm. Cardiac function as measured by LVEF, end-diastolic and end-systolic volumes, and cardiac output did not change during T3-treatment and neither did the neurohormonal profile. There were no side-effects in terms of cardiac arrhythmias and no change in resting heart rate.

CONCLUSIONS: The present study does not support the hypothesis that oral T3 treatment might be beneficial to patients with chronic, stable systolic HF with a modest degree of reduced LVEF and low-normal serum T3 concentrations. The study included both functional studies of heart contractility as well as measures of the neurohormonal activation. This article is protected by copyright. All rights reserved.

Original languageEnglish
JournalClinical Endocrinology
Volume83
Issue number6
Pages (from-to)931-7
Number of pages7
ISSN0300-0664
DOIs
Publication statusPublished - Dec 2015

ID: 45363788